Interview: Madhusudhan Venkatachari – CEO, Natco Pharma Canada
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Address: NATCO HOUSERoad No.2, Banjara HillsHyderabad-500 033,India
Tel: +91-40-2354 7532
Web: http://www.natcopharma.co.in/
NATCO Pharma Limited is an Indian enterprise molded by global aspirations. This has always demanded a preparedness and long- term organizational vision that can encompass the turbulence’s and paradoxes of shifting terms and terrain’s of business.
Background
Beginning:- NATCO PHARMA was promoted by Mr. V.C. Nannapaneni in the year 1981 as a Private Limited Company to be in the business of Research, Developing, Manufacturing and Marketing of Pharmaceutical Substances and Finished Dosage forms for Indian and International markets. NATCO PHARMA began operations in 1984 in Andhra Pradesh, India.
First Success:- In the first year of its operations it achieved a sales figure of Rs. 0.5 million. The company’s first product was Cardicap, which is an Anti-Anginal drug. Since then the company has introduced many dosage forms into the market. By 1985 it had dosage forms in Cardiovascular, Anti-cold, Anti-Asthmatic and Antibiotic segments. NATCO has the credit of having pioneered Time Release Technology in India.
The Journey:- NATCO PHARMA was ranked 82nd in sales among Indian Pharmaceutical companies in 1994. NATCO also has the credit of being one of the largest contract manufacturers in India. Some of the well-known companies like Ranbaxy, Dr. Reddy’s Laboratories, John Wyeth etc. get their products manufactured by NATCO. NATCO PHARMA grew in size when three companies merged with it.
NATCO Parenterals Limited
Dr. Karanth Pharma Labs Private Limited
NATCO Laboratories Limited
Today:- NATCO PHARMA LIMITED, which began its operations as a single unit with 20 employees, today has four manufacturing facilities and employs around 1500 people. It has an on-line data for Analysis and decision making. Consistently ranked among the fastest growing pharmaceutical companies in the country, Natco is utilizing its collective experience to kick start its future plans as a global company. Respected for Quality, Performance, Care, Responsibility and for creation and maximization of wealth for its shareholders NATCO Pharma Limited, the post-merger organization represents a strategic stage in NATCO’s constant evolution as the Complete Pharma Company.
TIGI
URINAT
PRIMANAT
AMINAT
VORIZOL
NATCLOVIR
NATFLU
X-VIR
BUNIDE-CR
OMENAT
NATZOLD
BANDRONE 150
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Compared to 5 years ago, MNCs have increased their presence in India. Some even have become market leaders, particularly through acquisitions of domestic players. How is this redistributing the game…
Writing in the March 2022 edition of DIA’s Global Forum magazine, Ananya Chakraborty from the Vydehi Institute of Medical Sciences & Research Centre outlines the key factors behind India’s successful…
The Indian pharma market clocked up double-digit growth of around 15 percent in 2021 (compared to three percent in 2020), driven primarily – but not only – by products related…
The latest news from Indian pharm and healthcare, including Piramal Enterprises’ decision to demerge and list its pharma arm, the country’s 15 pharma billionaires, Danish CNS firm Lundbeck’s decision to…
The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis…
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in the latest national budget; predictions of rapid growth in the coming decade; Cipla’s…
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages. Shortages and Price…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia…
See our Cookie Privacy Policy Here
